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Introduction {#cam4669-sec-0004}
============

Aggressive fibromatosis (AF), also known as desmoid‐type fibromatosis, is a rare, locally aggressive nonmetastasizing fibroblastic proliferation with an incidence of 0.2--0.4 per 100,000 cases/year. It mainly affects young to middle‐aged adults, but children are also sometimes involved [1](#cam4669-bib-0001){ref-type="ref"}. Its growth may be fairly slow, lasting over several years and it can appear nearly anywhere in the body [2](#cam4669-bib-0002){ref-type="ref"}.

The pathogenesis of AF is not completely understood, although many factors can be implicated in its inception and progression, such as a genetic predisposition (familial adenomatous polyposis \[FAP\] and Gardner syndrome) [3](#cam4669-bib-0003){ref-type="ref"}.

The biological and clinical patterns of AF in children are generally considered the same as in adults and treatment recommendations are usually similar. Nowadays, a stepwise approach is generally adopted, involving "wait‐and‐see" and medical options, and local treatments that include nonmutilating surgery in selected cases [4](#cam4669-bib-0004){ref-type="ref"}, [5](#cam4669-bib-0005){ref-type="ref"}, [6](#cam4669-bib-0006){ref-type="ref"}, [7](#cam4669-bib-0007){ref-type="ref"}, [8](#cam4669-bib-0008){ref-type="ref"}, [9](#cam4669-bib-0009){ref-type="ref"}, [10](#cam4669-bib-0010){ref-type="ref"}.

As in adults, AF in children may occur sporadically or in association with FAP; in both settings, an activation of the Wnt/beta‐catenin signaling has been documented [11](#cam4669-bib-0011){ref-type="ref"}. Consistently, more than 60% of sporadic cases of pediatric AF show nuclear beta‐catenin expression and mutations of its gene *CTNNB1*, whereas syndromic pediatric AF exhibit adenomatous polyposis coli (*APC)* germline mutations [12](#cam4669-bib-0012){ref-type="ref"}.

The *CTNNB1* somatic mutations seen in sporadic pediatric AF are clustered in two codons and are represented exclusively by three different types of single‐nucleotide substitution leading to the amino acid changes T41A, S45F, and S45P. Intriguingly, Bo et al. [12](#cam4669-bib-0012){ref-type="ref"}. found that the S45F mutation occurred mainly in recurrent pediatric cases, whereas the T41A mutation was most frequently seen in primary‐onset cases, suggesting that S45F mutations may represent a risk factor for recurrence, as in surgically treated adult AF [13](#cam4669-bib-0013){ref-type="ref"}.

Aside from the *CTNNB1* and *APC* mutations, the genetic profile of pediatric AF has been poorly characterized. A few molecular analyses have been performed on adult AF using comparative genomic hybridization or high‐density single‐nucleotide polymorphism array, and shown loss of 5q (including the *APC* locus), 6q and 8p23, but such studies are completely lacking in pediatric AF [14](#cam4669-bib-0014){ref-type="ref"}, [15](#cam4669-bib-0015){ref-type="ref"}.

As in many other soft tissue sarcomas, it remains to be seen whether AF has the same biological background and the same clinical behavior when it occurs in children as opposed to adults.

The aim of this study was to gain some insight on the mutational spectrum of pediatric AF, comparing it with its adult counterpart, in an effort to identify potential biomarkers that might be used as prognostic factors or therapeutic targets.

Material and Methods {#cam4669-sec-0005}
====================

Patients and samples {#cam4669-sec-0006}
--------------------

Twenty‐eight primary pediatric AFs treated at the IRCCS Istituto Nazionale dei Tumori in Milan between 1990 and 2011 were considered in this study. The characteristics of the patients and their disease are described in Table [1](#cam4669-tbl-0001){ref-type="table-wrap"}. Eleven patients underwent biopsy, 13 nonradical surgery, and four radical surgery. Among patients underwent biopsy, four received chemotherapy (low‐dose chemotherapy, i.e., methotrexate and vinblastine in two patients and methotrexate and vinorelbine in three cases) immediately after diagnosis, while five patients received chemotherapy (methotrexate and vinorelbine in four cases and vincristine + actinomycin D + cyclophosphamide in one case) after evidence of progression.

###### 

Clinical, *CTNNB1*, and adenomatous polyposis coli Sanger sequencing data in pediatric sporadic aggressive fibromatosis

  N.   Sex/age    Type               Site                        *CTNNB1*      *APC MCR*
  ---- ---------- ------------------ --------------------------- ------------- -----------
  1    f/15       Sporadic           Proximal lower limb         T41A          nd
  2    m/3        Sporadic           H&N                         T41A          nd
  3    f/12       Sporadic           Proximal lower limb         T41A          nd
  4    f/18       Sporadic           Trunk + Abdomen             T41A          nd
  5    m/2        Sporadic           H&N                         T41A          nd
  6    f/6        Sporadic           H&N                         T41A          nd
  7    f/0.2      Sporadic           H&N                         T41A          nd
  8    m/18       Sporadic           Trunk                       T41A + S45F   nd
  9    m/2        Sporadic           Trunk + Distal upper limb   S45F          nd
  10   m/9        Sporadic           H&N                         S45F          nd
  11   m/18       Sporadic           Distal lower limb           S45F          nd
  12   f/12       Sporadic           Proximal upper limb         S45F          nd
  13   f/18       Sporadic           Abdominal wall              S45F          nd
  14   m/18       Sporadic           Distal lower limb           S45P          nd
  15   f/12       Sporadic           Distal lower limb           S45P          nd
  16   m/4        Sporadic           Proximal lower limb         S45P          nd
  17   f/18       Sporadic           Proximal lower limb         S45P          nd
  18   f/18       Sporadic           Distal lower limb           S45P          nd
  19   m/14       Gardner syndrome   Abdominal wall              wt            wt
  20   f/15       Sporadic           Proximal lower limb         wt            wt
  21   f/15       Gardner syndrome   Abdomen                     wt            wt
  22   f/13       Sporadic           Trunk                       wt            E1544K
  23   m/5        Sporadic           Distal upper limb           wt            wt
  24   m/7        Sporadic           Trunk                       wt            wt
  25   f/9        Sporadic           Distal upper limb           wt            wt
  26   f/14       Sporadic           Distal lower limb           wt            na
  27   f/14       Sporadic           Proximal lower limb         wt            na
  28   3 months   Sporadic           H&N                         wt            wt

f, female; m, male; wt, wild type; nd, not done; na, not assessable; H&N, head and neck; MCR, mutated cluster region.
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The study sample was compared with a group of 33 surgically treated patients with sporadic adult AF, selected on the grounds of their known *CTNNB1* mutational status, whose characteristics are detailed in Table [2](#cam4669-tbl-0002){ref-type="table-wrap"}.

###### 

Clinical, next‐generation sequencing (NGS), and Sanger sequencing data in adult aggressive fibromatosis

  N.     Sex/age (years)     Type       Site                      *CTNNB1*Sanger   NGS                  
  ------ ------------------- ---------- ------------------------- ---------------- --------------- ---- ----
  1      f/47                Sporadic   Abdominal wall            T41A             *CTNNB1* T41A        
  2      f/60                Sporadic   Proximal upper limb       T41A             *CTNNB1* T41A        
  3      m/27                Sporadic   Proximal lower limb       T41A             *CTNNB1* T41A        
  4      f/32                Sporadic   Abdominal wall            S45F             *CTNNB1* S45F        
  5      m/46                Sporadic   Trunk                     S45F             *CTNNB1* S45F        
  6      f/36                Sporadic   Abdominal wall            S45P             *CTNNB1* S45P        
  7      f/35                Sporadic   Chest                     wt               No mutation          
  8      f/60                Sporadic   Peritoneum                wt               No mutation          
  9      f/35                Sporadic   Abdominal wall            wt               No mutation          
  10     f/65                Sporadic   Proximal lower limb       wt               *CTNNB1* T41A        
         Sanger sequencing                                                                              
  AKT1   BRAF                TP53                                                                       
  11     m                   Sporadic   Chest wall                T41A             wt              wt   wt
  12     f/32                Sporadic   Shoulder                  T41A             wt              wt   wt
  13     f/43                Sporadic   Abdomen                   T41A             wt              wt   wt
  14     m/34                Sporadic   Abdomen                   T41A             wt              wt   wt
  15     f/24                Sporadic   Abdominal wall            T41A             wt              wt   wt
  16     f/31                Sporadic   Abdominal wall            T41A             wt              wt   wt
  17     m/31                Sporadic   Trunk                     T41A             wt              wt   wt
  18     f/49                Sporadic   Mesentery                 T41A             wt              wt   wt
  19     f/28                Sporadic   Abdomen                   T41A             wt              wt   wt
  20     f/31                Sporadic   Abdominal wall            S45F             wt              wt   wt
  21     f/42                Sporadic   Proximal lower limb       S45F             wt              wt   wt
  22     f/35                Sporadic   Abdominal wall            S45F             wt              wt   wt
  23     m/50                Sporadic   Proximal lower limb       S45F             wt              wt   wt
  24     f/41                Sporadic   Abdominal wall            S45F             wt              wt   wt
  25     f/31                Sporadic   Abdominal wall            S45P             wt              wt   wt
  26     f/37                Sporadic   Abdominal wall            S45P             wt              wt   wt
  27     f/34                Sporadic   Abdominal wall            S45P             wt              wt   wt
  28     m/32                Sporadic   Abdomen                   wt               wt              wt   wt
  29     m/61                Sporadic   Trunk                     wt               wt              wt   wt
  30     f/70                Sporadic   Chest wall                wt               wt              wt   wt
  31     f/36                Sporadic   Proximal lower limb       wt               wt              wt   wt
  32     f/39                Sporadic   Abdominal wall            wt               wt              wt   wt
  33     m/36                Sporadic   Abdomen‐retroperitoneum   wt               wt              wt   wt
                                                                  70%              0               0    0

f, female; m, male; wt, wild type.
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DNA extraction {#cam4669-sec-0007}
--------------

Genomic DNA was extracted from 5 *μ*m sections cut from formalin‐fixed and paraffin‐embedded (FFPE) tumor samples with the GeneRead DNA FFPE kit (Qiagen, Hilden, Germany), according to the manufacturer\'s instructions.

Sanger sequencing {#cam4669-sec-0008}
-----------------

PCR was performed using specific primers for *CTNNB1* (exon 3), *BRAF* (exon 15), and *TP53* (exon 8), as described elsewhere [16](#cam4669-bib-0016){ref-type="ref"}. The primers used to amplify *AKT1* (exon 2), *RET* (exon 11), and *APC* (the mutation cluster region in exon 15 where most of the mutations segregate) are listed in Table [3](#cam4669-tbl-0003){ref-type="table-wrap"}.

###### 

Primers used for Sanger sequencing

  Gene                                              Primers
  ------------------------------------------------- --------------------------------
  Adenomatous polyposis coli (APC) EXON 15 PART 1   Fw 5′‐TGAAGAGAAACGTCATGTGGA‐3′
  Rev 5′‐CTTTGCAAGTGGCAGCCTTT‐3′                    
  APC EXON 15 PART 2                                Fw 5′‐AAGTGGTCAGCCTCAAAAGG‐3′
  Rev 5′‐GTGACACTGCTGGAACTTCG‐3′                    
  APC EXON 15 PART 3                                Fw 5′‐GATCCTGTGAGCGAAGTTCC‐3′
  Rev 5′‐AACATGAGTGGGGTCTCCTG‐3′                    
  APC EXON 15 PART 4                                Fw 5′‐ACACCCAAAAGTCCACCTGA‐3′
  Rev 5′‐ACTTCTCGCTTGGTTTGAGC‐3′                    
  APC EXON 15 PART 5                                Fw 5′‐AGCTCAAACCAAGCGAGAAG‐3′
  Rev 5′‐TTTCCTGAACTGGAGGCATT‐3′                    
  APC EXON 15 PART 6                                Fw 5′‐GCCTCCAGTTCAGGAAAATG‐3′
  Rev 5′‐ACAGGCAGCTGACTTGGTTT‐3′                    
  APC EXON 15 PART 7                                Fw 5′‐AGCCCAGACTGCTTCAAAAT‐3′
  Rev 5′‐TGCCCCTCCTCTAACTCCTT‐3′                    
  AKT1 EXON 2                                       Fw 5′‐CGAAGGTCTGACGGGTAGAG‐3′
  Rev 5′‐CGCCACAGAGAAGTTGTTGA‐3′                    
  RET EXON 11                                       Fw 5′‐AGGGATAGGGCCTGGGCTTC‐3′
  Rev 5′‐GACCTGGTTCTCCATGGAGTC‐3′                   
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The PCR products were submitted to direct sequencing using a 3500 DX Genetic Analyzer (Applied Biosystems, Foster City, CA) and then assessed with the ChromasPro software.

Next‐generation sequencing (NGS) {#cam4669-sec-0009}
--------------------------------

The 50‐gene Ion AmpliSeq Cancer Hotspot Panel v2 (Life Technologies) with the Ion‐Torrent^™^ Personal Genome Machine platform (Life Technologies, Foster city, CA, USA) was used in all experiments. This panel is designed to amplify 207 amplicons covering about 2800 COSMIC mutations from 50 oncogenes and tumor suppressor genes commonly mutated in human cancers (ABL1, AKT1, anaplastic lymphoma kinase (ALK), APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR/VEGFR2, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL).

The Ion AmpliSeq Library Kit 2.0 (Life Technologies) was used to amplify 40 ng of DNA according to the manufacturer\'s instructions (MAN0006735 rev 5.0). The amplicons were partially digested with FuPa Reagent (Life Technologies), ligated to P1 and barcode adapters using DNA ligase. Barcoded libraries were purified using AMPure Beads XP (Beckman Coulter, Brea, CA, USA) and PCR‐amplified for a total of five cycles. After a second round of purification with AMPure Beads, the amplified libraries were measured for size and tested for quality using the Agilent Bio Analyzer DNA High Sensitivity kit (Agilent Technologies, Santa Clara, CA, USA), and quantified using the Qubit dsDNA HS kit (Invitrogen, Life Technologies, Carlsbad, CA, USA). Emulsion PCR and sample enrichment were completed using the IonOne Touch 2 instrument, the emulsion PCR master‐mix, the Ion sphere particles and Dynabeads MyOne Streptavidin C1 beads (Life Technologies), according to the manufacturer\'s instructions (Life Technologies). Sequencing was done on Ion Torrent PGM using Ion 316 Chips and the Ion‐PGM 200 sequencing kit (Life Technologies), according to the manufacturer\'s instructions.

PGM sequencing data were initially processed using the Ion Torrent platform‐specific Torrent Suite software to generate sequence readouts, align them on the reference genome Hg19, trim the adapter sequences, filter, and discard any poor signal‐profile readouts. Variant calling from the sequencing data was done with the Variant Caller plug‐in. The filtered variants were examined visually using the Integrative Genomic Viewer tool to check their quality level and confirm the variant\'s presence on both the "+" and the "−" strand. The resulting variants were then recorded using the Ensemble Variant Effect Predictor pipeline, COSMIC database, dbSNP database, and MyCancerGenome database (<http://www.mycancergenome.org/>). Information on the distribution of mutated genes in lung cancer was obtained from online catalogs of somatic mutations, such as Cosmic (<http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/>), ClinVar of the National Center for Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov/clinvar/>), the NCBI\'s Entrez Gene database (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=gene>), and the GeneCards of the Weizmann Institute of Science, Israel (<http://www.genecards.org/>).

Statistical analysis {#cam4669-sec-0010}
--------------------

The prognostic analyses focused on the effects of the *CTNNB1*,*AKT1*, and *BRAF* mutations in pediatric AF patients. The study endpoint was recurrence‐free survival (RFS), and the time to the event was calculated from the date of surgery to the date of relapse or death, or it was censored as at the date of the latest uneventful follow‐up. RFS curves were estimated using the Kaplan--Meier method and were compared statistically using the log‐rank test.

Results {#cam4669-sec-0011}
=======

Pediatric AF mutation analysis {#cam4669-sec-0012}
------------------------------

### *β*‐catenin and *APC* Sanger sequencing {#cam4669-sec-0013}

Twenty‐eight patients (M/F: 18/10) with a median age of 12 years (range 2 months--18 years) were assessed. Two patients with tumors arising in the abdominal wall had Gardner syndrome. The whole blood sample of only one of these two syndromic patients was subjected few years ago to the mutational analysis of the whole APC gene that revealed a germline mutation, as expected. This analysis was not performed for the second patient during its follow‐up.

The 28 FFPE samples of pediatric AF were analyzed for *CTNNB1* mutations by Sanger sequencing, which revealed this mutation in 18 (64%) cases (Table [1](#cam4669-tbl-0001){ref-type="table-wrap"}). The mutations found were as follows: ACC\>GCC T41A (28%), TCT\>TTT S45F (21%), and TCT\>CCT S45P (18%) cases. Curiously, one case had both T41A and S45F mutations.

Since *CTNNB1* and *APC* mutations are generally mutually exclusive in AF, as in other tumors, nine of the 10 remaining cases carrying a *CTNNB1* wild type (wt) successfully underwent sequencing of APC. Since we analyzed FFPE samples, we sequenced exclusively the small part of the *APC* gene corresponding to the Mutated Cluster Region (MCR) and we found the missense mutation GAA\>AAA E1544K in one tumor (10% of cases) (Table [1](#cam4669-tbl-0001){ref-type="table-wrap"}). The MCR of two patients with Gardner syndrome showed no mutation. Given that no peripheral blood lymphocytes were available for this retrospective study, it was impossible the sequencing of the whole *APC* to assess the occurrence of germline mutations in the two cases with Gardner syndrome, or to check for the absence of the E1544K *APC* mutation in normal tissue and thus exclude Gardner syndrome or FAP. The extended follow‐up nonetheless makes us confident of the clinical diagnosis of Gardner syndrome or sporadic AF.

### NGS {#cam4669-sec-0014}

To better characterize the genotype of pediatric AF, NGS was performed in 16 sporadic cases (six with T41A, two with S45F, four with S45P, one with T41A+S45F, and three with C*TNNB1* wt) using a panel of 50 oncogenes and tumor suppressor genes.

In addition to confirming the findings for *CTNNB1* and *APC* obtained by Sanger sequencing, NGS revealed further mutations in five cases (31%), including: *AKT1* E17K (25%); *BRAF* V600E (12%) (Fig. [1](#cam4669-fig-0001){ref-type="fig"}A); *TP53* R273H (6%); and *RET* V648I (6%) (Table [4](#cam4669-tbl-0004){ref-type="table-wrap"}).

![Mutational analysis in pediatric aggressive fibromatosis (AF). Next‐generation sequencing (NGS) (A) and Sanger sequencing (B) revealed *AKT1* E17K and *BRAF* V600E mutations.](CAM4-5-1204-g001){#cam4669-fig-0001}

###### 

Next‐generation sequencing in pediatric aggressive fibromatosis

       Mutation      Polymorphism                                                          
  ---- ------------- -------------- ------- ------- ------- ------- ------- ------ ------- -------
  1    T41A          E17K           V600E   R273H                   I391M                  
  2    T41A                                                 Q472H                          
  3    T41A                                                 Q472H                          
  4    T41A                                                 Q472H   I391M                  
  5    T41A                                                                 P72R           
  6    T41A                         V600E                                                  
  8    T41A + S45F                                          Q472H           P72R           
  9    S45F                                         V648I                                  M541L
  11   S45F                                                 Q472H           P72R           
  14   S45P          E17K                                   Q472H                          
  15   S45P                                                 Q472H                          
  17   S45P          E17K                                           I391M          F386L   
  18   S45P                                                                        F386L   
  20   wt                                                                                  
  23   wt            E17K                                   Q472H   I391M                  
  27   wt                                                   Q472H   I391M                  M541L
                     25%            12%     6%      6%      56%     31%     19%    12%     12%

wt, wild type; Q472H, variant able to increase VEGFR2 phosphorylation after VEGFA stimulation in *vitro \[* [25](#cam4669-bib-0025){ref-type="ref"} *\];* M541L, KIT variant with controversial impact on fibromatosis response to imatinib [17](#cam4669-bib-0017){ref-type="ref"}, [18](#cam4669-bib-0018){ref-type="ref"}, [19](#cam4669-bib-0019){ref-type="ref"}; P72R, p53 variant with high apoptotic potential and cytoplasmic localization able to influence the cytosolic functions of the p53 protein [29](#cam4669-bib-0029){ref-type="ref"}.

John Wiley & Sons, Ltd

We also found some known polymorphisms such as the Q472H VEGFR2 (56%), I391M PIK3CA (31%), P72R TP53 (19%), F386L FGFR3 (12%), and M541L c‐KIT (12%) variants (Table [4](#cam4669-tbl-0004){ref-type="table-wrap"}). In particular, the M541L variant of c‐KIT has already been described in adult AF, where an association with AF tumorigenesis is unlikely, and its impact on response to imatinib remains controversial [17](#cam4669-bib-0017){ref-type="ref"}, [18](#cam4669-bib-0018){ref-type="ref"}, [19](#cam4669-bib-0019){ref-type="ref"}.

### *AKT1*,*BRAF,* TP53, and *RET* Sanger sequencing {#cam4669-sec-0015}

All the mutations found by NGS were confirmed by Sanger resequencing. Given the sizable proportion of *AKT1*,*BRAF*, and *TP53* mutations observed using NGS, these three genes were also sequenced directly in another 10 cases of pediatric AF. We were unable to analyze two cases because of the excessively small amount of tumor material available. *AKT1* and *BRAF* mutations were found in 40% and 30% cases, respectively (Fig. [1](#cam4669-fig-0001){ref-type="fig"}B). *TP53* analysis was successfully completed in only five cases, one of which (20%) carried the R273H mutation.

When the NGS and Sanger sequencing data were combined, after *CTNNB1, AKT1* emerged as the most frequently mutated gene (31%) (Table [5](#cam4669-tbl-0005){ref-type="table-wrap"}). The missense mutation E17K was seen in 2/7 T41A (28%), 2/4 S45P (50%), and 4/9 wt cases (44%), but in none of the S45F mutant AF. The *BRAF* V600E activating mutation occurred in five cases (19%), that is in 3/7 T41A (43%) and 2/9 wt AF (22%), whereas the *TP53* R273H mutation was observed in two (9%) cases. The *APC* mutation occurred in only one case (4%).

###### 

Combined Sanger and next‐generation sequencing results in pediatric aggressive fibromatosis

       Mutation                                    
  ---- ------------- -------- --------- ---------- ---------------
  1    T41A          wt       E17K^a^   V600E^a^   R273H^d,\ nf^
  2    T41A          wt       wt        wt         wt
  3    T41A          wt       wt        wt         wt
  4    T41A          wt       wt        wt         wt
  5    T41A          wt       wt        wt         wt
  6    T41A          wt       wt        V600E^a^   wt
  7    T41A          ND       E17K^a^   V600E^a^   na
  8    T41A + S45F   wt       wt        wt         wt
  9    S45F          wt       wt        wt         wt
  10   S45F          ND       wt        wt         na
  11   S45F          wt       wt        wt         wt
  12   S45F          wt       wt        wt         wt
  13   S45F          ND       wt        wt         wt
  14   S45P          wt       E17K^a^   wt         wt
  15   S45P          wt       wt        wt         wt
  16   S45P          ND       na        na         na
  17   S45P          wt       E17K^a^   wt         wt
  18   S45P          wt       wt        wt         wt
  19   wt            wt       wt        V600E^a^   R273H^d,\ nf^
  20   wt            wt       wt        wt         wt
  21   wt            wt       wt        wt         na
  22   wt            E1544K   E17K^a^   wt         na
  23   wt            wt       E17K^a^   wt         wt
  24   wt            wt       E17K^a^   V600E^a^   wt
  25   wt            wt       na        na         na
  26   wt            na       wt        wt         wt
  27   wt            wt       wt        wt         wt
  28   wt            wt       E17K^a^   wt         na
       64%           4%       31%       19%        9%

na, not assessable; ND, not done; wt, wild type; *APC,* adenomatous polyposis coli; MCR, mutated cluster region; a, activating mutation; d, disruptive mutation [30](#cam4669-bib-0030){ref-type="ref"}; nf, nonfunctional mutation [31](#cam4669-bib-0031){ref-type="ref"}
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Considering all the genes analyzed, there were 14 cases with one mutation, six with two, one with three, and one with four mutations, while five cases revealed none.

Adult AF mutational analysis {#cam4669-sec-0016}
----------------------------

### NGS {#cam4669-sec-0017}

We analyzed 10 adult sporadic AFs selected on the grounds of their previously established *CTNNB1* mutational status (three T41A, two S45F, one S45P, and four wt). No mutations other than *CTNNB1* came to light (Table [2](#cam4669-tbl-0002){ref-type="table-wrap"}). Interestingly, NGS revealed the T41A mutation in a case classified as wt on Sanger sequencing (case number 10). The only polymorphism observed was Q472H VEGFR2 (40%).

### *AKT1*,*BRAF*, and *TP53* Sanger sequencing {#cam4669-sec-0018}

Twenty‐three additional adult cases of sporadic AF (nine T41A; five S45F; three S45P, six wt) were submitted to Sanger sequencing of the three additional genes found mutated in pediatric AF (Table [2](#cam4669-tbl-0002){ref-type="table-wrap"}), and they all proved to be wt for *AKT1*,*BRAF*, and *TP53*.

Pooling the NGS and Sanger sequencing data, 36 sporadic adult AFs were analyzed successfully and no mutations other than *CTNNB1* were found.

Recurrence‐free survival in pediatric AF {#cam4669-sec-0019}
----------------------------------------

The prognostic analyses focused on the effects of *β*‐catenin, *AKT1*, and *BRAF* mutations in pediatric patients. With a median follow‐up of 93 months (range between 21--246 months), the estimated 3‐year and 5‐year RFS rates were 45.5%, for the series as a whole.

For the patients with *CTNNB1* mutations, the estimated 3‐year and 5‐year RFS rates were: 20% at both time points for patients with the 45F mutation; 43% for patients with the 41A mutation; and 20% and 0% for patients with the 45P mutation. Patients who were wt for *CTNNB1* mutations had a 3‐year and 5‐year RFS rate of 60% at both time points. (Fig. [2](#cam4669-fig-0002){ref-type="fig"}A). When wt and all *CTNNB1* mutated patients were compared, the 3‐ and 5‐year RFS rates were 60% and 28%, respectively (*P *= 0.078; Fig. [2](#cam4669-fig-0002){ref-type="fig"}B).

![Recurrence‐free survival (RFS) curves in pediatric aggressive fibromatosis (AF). RFS is illustrated in patients by specific *CTNNB1* mutations (A) *CTNNB1* mutation versus wild type (B) *AKT1* mutation (C) *BRAF* mutation (D).](CAM4-5-1204-g002){#cam4669-fig-0002}

Eight patients had a *AKT1* mutation: the estimated 3‐year and 5‐year RFS rates for these patients were both 62.5%, as opposed to 30% for the *AKT1* wt patients (*P *= 0.02469) (Fig. [2](#cam4669-fig-0002){ref-type="fig"}C).

Five patients had a *BRAF* mutation: the estimated 3‐year and 5‐year RFS rates for these patients were 80% and 60%, as opposed to 33% for the *BRAF* wt patients (*P *= 0.1058) (Fig. [2](#cam4669-fig-0002){ref-type="fig"}D).

Nine patients had Q472H *VEGFR2* polymorphism: the estimated 3‐year and 5‐year RFS rates for H472 patients were both 22%, as opposed to 43% for Q472 patients (*P *= 0.38) (Fig. [3](#cam4669-fig-0003){ref-type="fig"}).

![Recurrence‐free survival (RFS) curves in pediatric aggressive fibromatosis (AF) according to Q472H VEGFR2 polymorphism.](CAM4-5-1204-g003){#cam4669-fig-0003}

We reported that five patients did not have any aforementioned mutations (cases \#20, 21, 25, 26, and 27): the estimated 3‐year and 5‐year RFS for this group was 40%, as opposed to 36% for mutated patients (*P *= 0.9).

Discussion {#cam4669-sec-0020}
==========

In our study, we obtained sequencing data on 50 cancer‐related genes in cases of pediatric AF and compared them with findings in the adult counterpart of AF, identifying significant differences mainly involving *AKT1* and *BRAF* mutations in pediatric AF.

This retrospective series of 28 pediatric AFs was characterized for Wnt/beta‐catenin alterations. As in the adult counterpart [13](#cam4669-bib-0013){ref-type="ref"}, *CTNNB1* genotyping revealed a particularly high rate (64%) of mutations in the two codons T41 and S45. In detail, the distribution of the types of mutation that we identified suggests a similar frequency between T41A (28%) and S45F (21%), unlike two previous studies reporting that T41A was the most common type of mutation seen in pediatric AF [11](#cam4669-bib-0011){ref-type="ref"}, [12](#cam4669-bib-0012){ref-type="ref"}, as in adult AF [13](#cam4669-bib-0013){ref-type="ref"}. We nonetheless confirmed that S45P (14%) was the least common mutation, in line with the literature [11](#cam4669-bib-0011){ref-type="ref"}. Based on our previous experience with 179 cases of completely resected, sporadic primary AF, judging from which tumors with the S45F mutation have a higher tendency for local recurrence [13](#cam4669-bib-0013){ref-type="ref"}, we explored the possible prognostic role of specific mutations in pediatric AF. We found no statistically significant difference in terms of RFS for wt cases, though there was evidence of a trend (Fig. [2](#cam4669-fig-0002){ref-type="fig"}B). Unfortunately, our results failed to demonstrate that S45F or any of the *CTNBB1* mutations could be useful as a molecular indicator of a higher likelihood of recurrence (probably because the number of patients considered here was not enough to reveal differences relating to the different types of mutation). Similar data were obtained by Wang [11](#cam4669-bib-0011){ref-type="ref"}, whereas one study found the S45F mutation more frequent in recurrent pediatric AF than in primary tumors [12](#cam4669-bib-0012){ref-type="ref"}. This matter deserves further investigation to establish clearly whether these different types of mutation confer a different phenotype, and whether *CTNNB1* mutational status might therefore be used as prognostic tool.

To broaden our limited molecular understanding of AF and seek potential new biomarkers for targeted therapy, we better characterized the pediatric AF genotype by performing NGS and Sanger sequencing, and comparing the results with findings in adult AF. To the best of our knowledge, this is the first report of the E17K *AKT1* mutation (31%) occurring frequently in pediatric AF. This mutation was found in *CTNNB1* wt and T41A and S45P mutant pediatric cases, but not in patients with the S45F mutation.

AKT1 kinase is one of the most frequently activated survival pathways in cancer, and the well‐studied E17K mutation in the pleckstrin homology (PH) domain of AKT1 stimulates downstream signaling and transforms cells, causing AKT1 activation by means of a rapid conformational drift that in turn increases the localization of the protein on the plasma membrane [20](#cam4669-bib-0020){ref-type="ref"}, [21](#cam4669-bib-0021){ref-type="ref"}. The presence of *AKT1* mutation might have clinical implications based on the preclinical evidence that this mutant has been found resistant to AKT1/2 inhibitor, suggesting that pediatric AF patients probably would not benefit from this target treatment [20](#cam4669-bib-0020){ref-type="ref"}.

A small proportion of our *CTNNB1* mutant or wt pediatric AF cases (19%) harbored the common *BRAF* V600E substitution that destabilizes this kinase\'s inactive conformation, leading to its constitutive activation. This finding deserves further investigation in order to explore BRAF as a potential therapeutic target in pediatric AF due to the current availability of several BRAF inhibitors.

We found a higher RFS rate for the *AKT1* or *BRAF* mutated cases of no statistical significance.

The R273H *TP53* mutation was observed in 2 (9%) cases. It is worth noting that---both in sporadic and FAP‐related adult AF---previous studies investigated p53 protein expression only by immunohistochemistry, showing that nuclear p53 immunostaining was associated with a higher risk of tumor recurrence [22](#cam4669-bib-0022){ref-type="ref"}, [23](#cam4669-bib-0023){ref-type="ref"}.

Interestingly, no *AKT1*,*BRAF*, or TP53 mutations were found in the series of 33 adult AFs that we selected on the grounds of their *CTNNB1* status; this would suggest that such alterations are a distinctive feature of pediatric AF that should be validated on independent series.

One pediatric case (6%) also revealed the V648I mutation in the human *RET* oncogene, a rare substitution reported in medullary thyroid carcinoma, a setting in which it was judged to be "non‐transforming" in the light of elegant *in silico* and *in vitro* analyses, and this raised some doubts as to whether V648I might represent the driving force behind the tumor [24](#cam4669-bib-0024){ref-type="ref"}. Although in AF, we cannot say for sure whether the ability of V648I to induce a tumoral transformation is related to particular predisposing genetic conditions, this mutation seems to have a marginal role in pediatric AF.

In a sizable proportion of both pediatric (56%) and adult (40%) cases of AF, NGS also revealed the Q472H VEGFR2 polymorphism that was the only genetic variant capable of increasing protein phosphorylation after VEGFA stimulation *in vitro* [25](#cam4669-bib-0025){ref-type="ref"}. The effect of Q472H on VEGFR2 function may be due to a more efficient binding to the ligand. The role of VEGFR2 in carcinogenesis and tumor progression is related to its well‐known proangiogenic effects, and the PDGFR‐B expression that we observed by IHC in all pediatric AF cases may go in the same direction, along with COX expression (data not shown). These results are in line with our previous findings of PDGFRB expression/phosphorylation in frozen samples of adult AF, and of PDGFRA too (in some of them at least), probably mediated by their cognate ligands [26](#cam4669-bib-0026){ref-type="ref"}. Unfortunately, we were unable to test the activation of these two receptors in our pediatric AF series owing to a shortage of frozen material. We speculate that the PDGFR expression, along with the Q472H VEGFR2 variant and the mutation‐mediated BRAF activation, might have a proangiogenic role in pediatric AF, favoring a response to multitarget anti‐angiogenic agents found active in the adult counterpart [27](#cam4669-bib-0027){ref-type="ref"}, [28](#cam4669-bib-0028){ref-type="ref"}.

In conclusion, our results suggest that the mutational spectrum of pediatric AF is more complex than in adult AF, being rich in *AKT1* and *BRAF,* as well as *CTNNB1* gene mutations. These intriguing findings could have clinical implications and warrant further investigation on a new and larger cohort of patients. We hopefully expect that our study could represent the rationale for a future international collaboration between pediatric oncologists involved in a so rare and peculiar disease.
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